- Home
- ITRG vs MAIA Comparison
ITRG vs MAIA Comparison
Compare ITRG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- MAIA
- Stock Information
- Founded
- ITRG 1997
- MAIA 2018
- Country
- ITRG Canada
- MAIA United States
- Employees
- ITRG N/A
- MAIA N/A
- Industry
- ITRG Precious Metals
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- MAIA Health Care
- Exchange
- ITRG Nasdaq
- MAIA Nasdaq
- Market Cap
- ITRG 497.8M
- MAIA 44.9M
- IPO Year
- ITRG N/A
- MAIA 2022
- Fundamental
- Price
- ITRG $2.86
- MAIA $0.92
- Analyst Decision
- ITRG Strong Buy
- MAIA
- Analyst Count
- ITRG 2
- MAIA 0
- Target Price
- ITRG $4.00
- MAIA N/A
- AVG Volume (30 Days)
- ITRG 2.3M
- MAIA 298.1K
- Earning Date
- ITRG 11-12-2025
- MAIA 11-07-2025
- Dividend Yield
- ITRG N/A
- MAIA N/A
- EPS Growth
- ITRG N/A
- MAIA N/A
- EPS
- ITRG 0.08
- MAIA N/A
- Revenue
- ITRG $219,125,000.00
- MAIA N/A
- Revenue This Year
- ITRG $939.47
- MAIA N/A
- Revenue Next Year
- ITRG $6.60
- MAIA N/A
- P/E Ratio
- ITRG $35.95
- MAIA N/A
- Revenue Growth
- ITRG N/A
- MAIA N/A
- 52 Week Low
- ITRG $0.79
- MAIA $0.87
- 52 Week High
- ITRG $3.49
- MAIA $2.74
- Technical
- Relative Strength Index (RSI)
- ITRG 48.41
- MAIA 31.20
- Support Level
- ITRG $2.84
- MAIA $0.87
- Resistance Level
- ITRG $3.12
- MAIA $1.09
- Average True Range (ATR)
- ITRG 0.22
- MAIA 0.08
- MACD
- ITRG -0.01
- MAIA -0.01
- Stochastic Oscillator
- ITRG 37.73
- MAIA 15.07
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.